<unk>  is an sodium-glucose co-transporter 2 (SGLT2) inhibitor that is FDA approved for the treatment of type 2 diabetes mellitus. It is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.   Common adverse reactions include female genital mycotic infections, urinary tract infection, and increased urination.
Canagliflozin
Linagliptin
Empagliflozin
Dapagliflozin
Liraglutide
Exenatide
Vildagliptin
Pioglitazone